Q3 EPS Forecast for Coya Therapeutics Increased by Analyst

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Coya Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.24) per share for the quarter, up from their previous forecast of ($0.50). The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.41) EPS.

Several other equities analysts also recently commented on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Tuesday, May 13th.

Coya Therapeutics Stock Down 3.2%

Shares of Coya Therapeutics stock opened at $5.67 on Wednesday. The stock’s fifty day moving average is $6.01 and its two-hundred day moving average is $6.15. The company has a market capitalization of $94.83 million, a PE ratio of -8.72 and a beta of 0.49. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, meeting the consensus estimate of ($0.44). The business had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. DME Capital Management LP grew its position in shares of Coya Therapeutics by 29.2% during the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after buying an additional 372,414 shares in the last quarter. AIGH Capital Management LLC grew its position in shares of Coya Therapeutics by 85.0% during the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock worth $6,883,000 after buying an additional 551,725 shares in the last quarter. CM Management LLC grew its position in shares of Coya Therapeutics by 25.0% during the 1st quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $1,294,000 after buying an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC bought a new position in shares of Coya Therapeutics during the 1st quarter worth $1,083,000. Finally, Geode Capital Management LLC grew its position in shares of Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock worth $863,000 after buying an additional 8,267 shares in the last quarter. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.